Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegeneration, Oncology, and Mechanotransduction Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for FLNA drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FLNA Recombinant Proteins: full-length, domain-specific (Rod domain, Actin-Binding Domain, CH1/CH2), and mutant variants (including PVNH-associated mutations). High purity (>95%), Endotoxin <1EU/μg, sequence verified, HEK293 expressed. | View FLNA Products |
| Gene Delivery | FLNA Promise-ORF / Lentivirus: full-length ORF for stable cell lines, suitable for mechanotransduction and rescue studies. High titer (>10⁸ TU/ml). | View FLNA Products |
| Benchmark Ab | Anti-FLNA Recombinant Monoclonal (e.g., Clone EP2405): validated for Western blot, IHC, IP, and IF. Sequence-defined positive control. | View FLNA Products |
| Validator | FLNA siRNA Set (multiple unique sequences): for knockdown validation and assay specificity controls in migration/invasion assays. | View FLNA Products |
| Related Target A | FLNB (Filamin B): Paralog protein for selectivity and counter-screening assays. | View FLNB Products |
| Related Target B | FLNC (Filamin C): Muscle-enriched paralog for off-target liability assessment. | View FLNC Products |
| Related Target C | ITGB1 (Integrin β1): Critical binding partner for focal adhesion and mechanosensing. | View ITGB1 Products |
| Related Target D | TLR4: Co-receptor involved in FLNA-mediated neuroinflammation. | View TLR4 Products |
| Related Target E | RAC1: Downstream signaling partner; required for migration assays. | View RAC1 Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Specificity (Altered vs Native) | HEK293 expressed proteins with physiological folding; domain constructs verified by CD spectroscopy. |
| Protein-Protein Interaction (PPI) Screening | High-purity (>95%) recombinant domains (Rod, Ig-like repeats) optimized for SPR/BLI; sequence verified. |
| Lack of Controls | Clinical Benchmark Antibodies and domain-truncated antigens included for reliable baselines. |
| False Positives in Assays | Validated siRNA for specificity checks; rescue assays supported. |
| Cross-species Evaluation | Human / Mouse / Cyno ortholog proteins available (>95% purity, sequence verified). |
| Paralog Selectivity (FLNB/FLNC) | Homolog panel with mass spec verification; distinct domain constructs ready. |
| Dimerization Interface Analysis | Monomeric vs Dimeric preparations with analytical SEC validation. |
| Intracellular Target Engagement | Cell-permeable TAT-fusion constructs; Lentivirus for stable overexpression lines. |
| Actin-Binding Validation | Native folded ABD with co-sedimentation assay protocols provided. |
Live FLNA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Resistance Research
- ➤ Latest Metastasis Inhibitor Research
- ➤ Mechanotransduction Mechanisms
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
FLNA (Filamin A) is a critical cytoskeletal crosslinking and scaffold protein that has emerged as an attractive yet challenging intracellular target in neurodegeneration, oncology, and mechanotransduction. In Alzheimer's disease, altered FLNA conformations drive neuroinflammation and tau hyperphosphorylation, leading to early clinical efforts with small-molecule modulators such as Cassava Sciences' Simufilam (PTI-125). In oncology, FLNA overexpression is linked to metastatic progression in breast, lung, and melanoma cancers, where it acts as a mechanical hub regulating cell migration, invasion, and drug resistance. The current R&D landscape is transitioning from genetic correlation studies to rational intracellular targeting, with diverse modalities including small-molecule PPI inhibitors, cell-penetrating peptides (CPPs), peptide/peptidomimetics, PROTACs, and mechanosensitive nanocarriers. Notably, FLNA mutations (e.g., PVNH1-associated mutations rs137853313, rs28935169) cause periventricular nodular heterotopia, a neurological disorder, underscoring the protein's importance in brain development. The next wave of innovation focuses on domain-specific PPI stabilization, paralog-selective degraders, and intracellular delivery strategies to overcome the size and localization barriers. Key players include academic consortia, biotech startups, and emerging pharma exploring allosteric inhibitors targeting the rod domain dimerization interface and cell-penetrating peptides blocking integrin-FLNA interactions.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Conformational Modulator) | Cassava Sciences (Simufilam), Academic Consortia | Alzheimer's Disease | Conformation-specific binding assay using recombinant FLNA domains (altered vs native) |
| Small Molecule (PPI Inhibitor) | Academic Consortia, Biotech Startups | Metastatic Breast Cancer, Melanoma, Solid Tumors | PPI disruption assay (SPR/BLI) with high-purity Rod domain proteins |
| Peptide / Peptidomimetic Inhibitor | Early-Stage Biotechnology | Prostate Cancer (AR axis) | PPI disruption assay (SPR/BLI) with high-purity FLNA repeat proteins |
| Cell-Penetrating Peptide (CPP) | Specialized Biotech | Brain Metastases (BBB penetration) | Intracellular delivery validation using TAT-fusion positive controls |
| Gene Therapy | Undisclosed | Periventricular Nodular Heterotopia (PVNH) | Expression validation using sequence-verified ORF and lentivirus |
| Targeted Protein Degradation (PROTAC) | Emerging Pharma | Drug-Resistant Tumors | Ubiquitination assay using full-length FLNA substrate |
| RNAi / siRNA | Discovery-Stage Programs | Solid Tumors | Knockdown validation via qPCR/Western using validated siRNA controls |